Theresa LaVallee

2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF

Nicola J. Mabjeesh, Daniel Escuín, Theresa LaVallee et al. · Cancer Cell · 2003 · 726 citations

Medicine, Cancer Biology, Oncology +12

Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial

Lacey Padrón, Deena M. Maurer, Mark H. O’Hara et al. · Nature Medicine · 2022 · 350 citations · Full text

Medicine, Oncology, Pharmacology +15

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study

Mark H. O’Hara, Eileen M. O’Reilly, Gauri R. Varadhachary et al. · The Lancet Oncology · 2020 · 301 citations

Medicine, Oncology, Pharmacology +15

Effects of Aging and Hypoxia-Inducible Factor-1 Activity on Angiogenic Cell Mobilization and Recovery of Perfusion After Limb Ischemia

Marta Bosch‐Marcé, Hiroaki Okuyama, Jacob Wesley et al. · Circulation Research · 2007 · 289 citations · Full text

Medicine, Cell Biology, Geriatric Medicine +17

Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce

Harriet M. Kluger, Hussein A. Tawbi, Maria Libera Ascierto et al. · Journal for ImmunoTherapy of Cancer · 2020 · 280 citations · Full text

Medicine, Immunology, Oncology +16